Literature DB >> 16388316

Chromosome abnormalities with prognostic impact in B-cell chronic lymphocytic leukemia.

Gábor Méhes1.   

Abstract

The detailed analysis of the biologic features led to a rapid increase in clinically relevant information in CLL. The recognition of the prognostic role of IgVH hypermutation status and related phenotypic changes (CD38, ZAP-70 expression) as well as of chromosome abnormalities defined by cytogenetic analysis enabled a refined classification of the disease. Improvements in karyotyping and the introduction of fluorescence in situ hybridization (FISH) in routine hematological diagnostics raised the detection rate of chromosomal aberrations to approx. 60-80% in CLL. Among them, deletions of 17p and 11q have been associated with unfavorable prognosis. The deletion of the p53 locus (17p13) was described as the strongest independent predictor for aggressive behavior, resistance to chemotherapy and early death. On the contrary, an isolated deletion at 13q14 or a normal karyotype was related with a long survival. Classical and molecular cytogenetic analysis became an important tool for individual risk estimation. Unlike any other approaches, cytogenetic monitoring reflects the genetic heterogeneity and clonal growth dynamics during the course of the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16388316     DOI: 10.1007/BF02893852

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  33 in total

1.  Characterization of a novel B-CLL candidate gene--DLEU7--located in the 13q14 tumor suppressor locus.

Authors:  Marianne Hammarsund; Martin M Corcoran; William Wilson; Chaoyong Zhu; Stefan Einhorn; Olle Sangfelt; Dan Grandér
Journal:  FEBS Lett       Date:  2004-01-02       Impact factor: 4.124

2.  Tools for molecular risk-stratification for clinical purposes: CLL as a prototype.

Authors:  Daphne de Jong; Laura J van't Veer
Journal:  Eur J Hum Genet       Date:  2004-06       Impact factor: 4.246

3.  Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia.

Authors:  D Capello; A Guarini; E Berra; F R Mauro; D Rossi; E Ghia; M Cerri; J Logan; R Foà; G Gaidano
Journal:  Leukemia       Date:  2004-12       Impact factor: 11.528

4.  Trisomy 12 in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: analysis by stage, immunophenotype, and morphology.

Authors:  T H Que; J G Marco; J Ellis; E Matutes; V B Babapulle; S Boyle; D Catovsky
Journal:  Blood       Date:  1993-07-15       Impact factor: 22.113

Review 5.  Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis.

Authors:  H Döhner; S Stilgenbauer; K Döhner; M Bentz; P Lichter
Journal:  J Mol Med (Berl)       Date:  1999-02       Impact factor: 4.599

Review 6.  Richter syndrome: biology, incidence, and therapeutic strategies.

Authors:  Apostolia-Maria Tsimberidou; Michael J Keating
Journal:  Cancer       Date:  2005-01-15       Impact factor: 6.860

7.  Relationship between the mutational status of VH genes and pathogenesis of diffuse large B-cell lymphoma in Richter's syndrome.

Authors:  B Timár; Z Fülöp; B Csernus; C Angster; A Bognár; A Szepesi; L Kopper; A Matolcsy
Journal:  Leukemia       Date:  2004-02       Impact factor: 11.528

8.  Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status.

Authors:  Christian Haslinger; Norbert Schweifer; Stephan Stilgenbauer; Hartmut Döhner; Peter Lichter; Norbert Kraut; Christian Stratowa; Roger Abseher
Journal:  J Clin Oncol       Date:  2004-10-01       Impact factor: 44.544

9.  Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses.

Authors:  Tatjana Stankovic; Mike Hubank; Debbie Cronin; Grant S Stewart; Danielle Fletcher; Colin R Bignell; Azra J Alvi; Belinda Austen; Victoria J Weston; Christopher Fegan; Philip J Byrd; Paul A H Moss; A Malcolm R Taylor
Journal:  Blood       Date:  2003-09-04       Impact factor: 22.113

10.  Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Authors:  A Rosenwald; A A Alizadeh; G Widhopf; R Simon; R E Davis; X Yu; L Yang; O K Pickeral; L Z Rassenti; J Powell; D Botstein; J C Byrd; M R Grever; B D Cheson; N Chiorazzi; W H Wilson; T J Kipps; P O Brown; L M Staudt
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

View more
  8 in total

1.  Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine.

Authors:  Jiawei Wang; Lian Li; Jiyuan Yang; Phillip M Clair; Martha J Glenn; Deborah M Stephens; D Christopher Radford; Ken M Kosak; Michael W Deininger; Paul J Shami; Jindřich Kopeček
Journal:  Nanomedicine       Date:  2019-01-09       Impact factor: 5.307

2.  Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia.

Authors:  Lingzhi Zhang; Fiona Murray; Laura Z Rassenti; Minya Pu; Colleen Kelly; Joan R Kanter; Andrew Greaves; Karen Messer; Thomas J Kipps; Paul A Insel
Journal:  Int J Cancer       Date:  2011-02-11       Impact factor: 7.396

3.  POLYMERIC BIOMATERIALS AND NANOMEDICINES.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Drug Deliv Sci Technol       Date:  2015-12-01       Impact factor: 3.981

4.  Drug-Free Macromolecular Therapeutics--A New Paradigm in Polymeric Nanomedicines.

Authors:  Te-Wei Chu; Jindřich Kopeček
Journal:  Biomater Sci       Date:  2015-07       Impact factor: 6.843

5.  The prognostic significance of 13q deletions of different sizes in patients with B-cell chronic lymphoproliferative disorders: a retrospective study.

Authors:  Shuhua Yi; Heng Li; Zengjun Li; Wenjie Xiong; Huimin Liu; Wei Liu; Rui Lv; Zhen Yu; Dehui Zou; Yan Xu; Gang An; Lugui Qiu
Journal:  Int J Hematol       Date:  2017-04-24       Impact factor: 2.490

6.  Toward personalized therapy for chronic lymphocytic leukemia: DSC and cDNA microarray assessment of two cases.

Authors:  Małgorzata Rogalińska; Ida Franiak-Pietryga; Jerzy Z Błoński; Paweł Góralski; Henryk Maciejewski; Agnieszka Janus; Paweł Robak; Marek Mirowski; Henryk Piekarski; Tadeusz Robak; Zofia M Kiliańska
Journal:  Cancer Biol Ther       Date:  2012-10-31       Impact factor: 4.742

7.  Molecular characterization of chronic lymphocytic leukemia patients with a high number of losses in 13q14.

Authors:  Ana Eugenia Rodríguez; Jose Ángel Hernández; Rocío Benito; Norma C Gutiérrez; Juan Luis García; María Hernández-Sánchez; Alberto Risueño; M Eugenia Sarasquete; Encarna Fermiñán; Rosa Fisac; Alfonso García de Coca; Guillermo Martín-Núñez; Natalia de Las Heras; Isabel Recio; Oliver Gutiérrez; Javier De Las Rivas; Marcos González; Jesús M Hernández-Rivas
Journal:  PLoS One       Date:  2012-11-13       Impact factor: 3.240

8.  Monoallelic and biallelic deletions of 13q14 in a group of CLL/SLL patients investigated by CGH Haematological Cancer and SNP array (8x60K).

Authors:  Beata Grygalewicz; Renata Woroniecka; Jolanta Rygier; Klaudia Borkowska; Iwona Rzepecka; Martyna Łukasik; Agnieszka Budziłowska; Grzegorz Rymkiewicz; Katarzyna Błachnio; Beata Nowakowska; Magdalena Bartnik; Monika Gos; Barbara Pieńkowska-Grela
Journal:  Mol Cytogenet       Date:  2016-01-06       Impact factor: 2.009

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.